UNSPSC 51283107: Caspofungin acetate

This classification denotes an antifungal agent with the molecular formula C52H88N10O15.2C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VUW370O5QE, chemically known as pneumocandin b0, 1-((4r,5s)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine)-5-((3r)-3-hydroxy-l-ornithine)-, diacetate (salt) but more generally known as caspofungin acetate, which bears US NIH Compound Identifier 123623. The base compound, Caspofungin, most often comes in base and acetate forms.

UNSPSC 51283107 Caspofungin acetate is a Commodity code, but recent state and local solicitations tagged under this code show minimal alignment with the pharmaceutical ingredient it names. The recent opportunities block contains four solicitations nominally assigned this code: one for naloxone and drug deactivation systems (Seminole County, Florida), one for direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission), one for medical and first aid supplies including respiratory equipment and cardiac monitoring devices (City of Tampa), and one for generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). None of these solicitations explicitly reference caspofungin acetate or antifungal pharmaceutical ingredients. The code shows activity across state health agencies, county public health departments, city fire and rescue services, and multistate cooperative purchasing vehicles, suggesting the code may be applied inconsistently or serve as a catch-all for pharmaceutical and medical supply procurement that does not fit narrower therapeutic categories.

Geographic spread includes Florida, Texas, Minnesota, and Oregon based on the recent opportunities. Representative recent solicitations include the City of Tampa's IFB 26P00145 for medical and first aid supplies due March 13, 2026 (estimated value $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, effective July 1, 2026. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs. Given the disconnect between the code's nominal pharmaceutical scope and the actual work being solicited, the code appears to carry limited signal for firms specifically pursuing caspofungin acetate supply contracts at the state and local level.